Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma

Therapeutic Advances in Hematology

Volumn 3, Issue 2, 2012, Pages 117-124

  Mateos, Maria Victoria ^a   San Miguel, Jesus F ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

bortezomib; intravenous and subcutaneous formulations; multiple myeloma

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE;

ANTINEOPLASTIC ACTIVITY; ASTHENIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER INCIDENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL PRACTICE; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PLASMA CELL DYSCRASIA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; RISK FACTOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

EID: 84993814033     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620711432020     Document Type: Review

References (25)

1. Adams J. Palombella V.J. Sausville E.A. Johnson J. Destree A. Lazarus D.D. et al. (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 2615–2622.
2. Cavo M. Tacchetti P. Patriarca F. Petrucci M.T. Pantani L. Galli M. et al. (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376: 2075–2085.
3. Harousseau J.L. Attal M. Avet-Loiseau H. Marit G. Caillot D. Mohty M. et al. (2010) Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 28: 4621–4629.
4. Hideshima T. Richardson P.G. Anderson K.C. (2003) Targeting proteasome inhibition in hematologic malignancies. Rev Clin Exp Hematol 7: 191–204.
5. Jagannath S. Barlogie B. Berenson J. Siegel D. Irwin D. Richardson P.G. et al. (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127: 165–172.
6. Jakubowiak A.J. Griffith K.A. Reece D.E. Hofmeister C.C. Lonial S. Zimmerman T.M. et al. (2011) Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1 / 2 Multiple Myeloma Research Consortium trial. Blood 118: 535–543.
7. Kumar S.K. Rajkumar S.V. Dispenzieri A. Lacy M.Q. Hayman S.R. Buadi F.K. et al. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111: 2516–2520.
8. Mateos M.V. Oriol A. Martinez-Lopez J. Gutierrez N. Teruel A.I. de Paz R. et al. (2010) Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 11: 934–941.
9. Mitch W.E. Goldberg A.L. (1996) Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 335: 1897–1905.
10. Mitsiades N. Mitsiades C.S. Richardson P.G. Poulaki V. Tai Y.T. Chauhan D. et al. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101: 2377–2380.
11. Moreau P. Coiteux V. Hulin C. Leleu X. van de Velde H. Acharya M. et al. (2008) Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica 93: 1908–1911.
12. Moreau P. Pylypenko H. Grosicki S. Karamanesht I. Leleu X. Grishunina M. et al. (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12: 431–440.
13. Orlowski R.Z. Nagler A. Sonneveld P. Blade J. Hajek R. Spencer A. et al. (2007) Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25: 3892–3901.
14. Orlowski R.Z. Stinchcombe T.E. Mitchell B.S. Shea T.C. Baldwin A.S. Stahl S. et al. (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20: 4420–4427.
15. Palombella V.J. Rando O.J. Goldberg A.L. Maniatis T. (1994) The ubiquitin-proteasome pathway is required for processing the NF-kappa B 1 precursor protein and the activation of NF-kappa B. Cell 78: 773–785.
16. Palumbo A. Bringhen S. Rossi D. Cavalli M. Larocca A. Ria R. et al. (2010) Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib–melphalan–prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 28: 5101–5109.
17. Rajkumar S.V. Richardson P.G. Hideshima T. Anderson K.C. (2005) Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23: 630–639.
18. Richardson P.G. Barlogie B. Berenson J. Singhal S. Jagannath S. Irwin D. et al. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609–2617.
19. Richardson P.G. Sonneveld P. Schuster M. Irwin D. Stadtmauer E. Facon T. et al. (2007) Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110: 3557–3560.
20. Richardson P.G. Sonneveld P. Schuster M.W. Irwin D. Stadtmauer E.A. Facon T. et al. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352: 2487–2498.
21. Richardson P.G. Weller E. Jagannath S. Avigan D.E. Alsina M. Schlossman R.L. et al. (2009) Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed / refractory multiple myeloma. J Clin Oncol 27: 5713–5719.
22. Richardson P.G. Weller E. Lonial S. Jakubowiak A.J. Jagannath S. Raje N.S. et al. (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116: 679–686.
23. Rosinol L. Cibeira M.T. Mateos M.V. Martinez J. Oriol A. Teruel A.I. et al. (2010) A phase III PETHEMA / GEM study of induction therapy prior autologous stem cell transplantation (ASCT) in multiple myeloma: superiority of VTD (bortezomib/thalidomide/dexamethasone) over TD and VBMCP / VBAD plus bortezomib. ASH Annual Meeting Abstracts 116 (21): 307.
24. San Miguel J.F. Schlag R. Khuageva N.K. Dimopoulos M.A. Shpilberg O. Kropff M. et al. (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359: 906–917.
25. Sonneveld P. Schmidt-Wolf I. van der Holt B. Jarari L.E. Bertsch U. Salwender H. et al. (2010) HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM). ASH Annual Meeting Abstracts 116 (21): 40.